The Pharma Data

DECEMBER 8, 2020

Blood disease trial participants given Vertex’s and CRISPR Therapeutics’ CRISPR/Cas9-based gene-editing therapy CTX001 demonstrated a “consistent and sustained response” to the treatment, according to new phase 1/2 trial data the companies have announced. To date, a total of 19 trial participants have been dosed with the gene therapy.

Therapies 52

Therapies Clinical Trials Trials Treatment 52

The Pharma Data

NOVEMBER 3, 2020

4, 2020 /PRNewswire/ — Q3 2020 highlights. m (-), including US launch of the scientifically proven digital therapies deprexis® and vorvida®. Updated financial outlook 2020. 2020 Jul-Sep. 2020 Jan-Sep. m (90.9).

Therapies 52

Therapies Production Pharmaceuticals Marketing 52

Advarra

NOVEMBER 29, 2022

The field of cell and gene therapies (CGT) is constantly evolving, and there has been significant progress in this area of research. However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines.

Therapies 52

Therapies Clinical Trials FDA Production 52

Drug Target Review

NOVEMBER 7, 2023

To reach the other 40 percent of those proteins, Stanford ChEM-H researchers pioneered lysosome targeting chimeras (LYTACs) in 2020. To test which patients are more likely to respond to LYTAC therapy, the level of neddylated CUL3 could be measured. Enzyme replacement therapy is a frequent treatment for these disorders.

Therapies 59

Therapies Science Disease Treatment 59

The Pharma Data

DECEMBER 21, 2020

The FDA granted cilta-cel Breakthrough Therapy and Orphan Drug designations in 2019, and the therapy received a PRIME Priority Medicines designation from the European Commission (EC) that same year and an Orphan Drug designation from the EC in February 2020. Source link.

Therapies 40

Therapies Licensing Licensing Clinical Development 40

The Pharma Data

NOVEMBER 18, 2020

Over the past decade, the world has witnessed unprecedented scale-up of antiretroviral therapy (ART), which has saved the lives of tens of millions of people. Between 2004 and 2020, 57 countries implemented surveys of HIV drug resistance using WHO-recommended methods (see map below), and 17 countries have plans to conduct surveys.

Laboratories 52

Laboratories Therapies Virus Government 52

The Pharma Data

NOVEMBER 18, 2020

Per the deal, Obsidian Therapeutics will provide its cytoDRiVE delivery platform to the university to speed research into TILs, which target tumors by reversing the expression of certain cancer-causing proteins via an oral therapy.

Therapies 52

Therapies Treatment Disease Research 52

The Pharma Data

OCTOBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Agios Pharmaceuticals, Inc. NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, November 5, 2020 at 8:00 a.m. CAMBRIDGE, Mass.,

International 52

International Disease Therapies Pharmaceuticals 52

Eye on FDA

MARCH 5, 2023

Note these numbers cover meetings about drug applications only, not including vaccines or cellular therapies. That said, beginning in 2020 meetings began skewing to more negative outcomes and 2022 was the first year where the number of negative outcomes outweighed the number of positive outcomes.

FDA 72

FDA Vaccine Drugs Therapies 72

The Pharma Data

JANUARY 12, 2021

Preliminary revenue for the fourth quarter of 2020 is expected to be approximately $40.6 Preliminary revenue for the fourth quarter of 2020 is expected to be approximately $40.6 Preliminary revenue for the full year 2020 is expected to be approximately $125.4 2020 was a transformational year for Vapotherm.

Therapies 52

Therapies Production Marketing Regulations 52

The Pharma Data

NOVEMBER 8, 2020

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. LONDON and RALEIGH, N.C.,

Therapies 52

Therapies Treatment Disease Hospitals 52

The Pharma Data

DECEMBER 7, 2020

Laser Therapy Promising for Drug-Resistant Child Epilepsy. “Compared to surgery, MRI-guided laser therapy can help reduce the risk of injury to critical brain structures and minimize serious neurological deficits,” a coauthor said in a statement. © 2020 HealthDay. Posted: December 2020. Professional.

Therapies 52

Therapies Drugs Hospitals Research 52

The Pharma Data

OCTOBER 21, 2020

22, 2020 (GLOBE NEWSWIRE) — Athenex, Inc. The Company’s current clinical pipeline is derived from four different platform technologies: (1) Orascovery, based on P-glycoprotein inhibitor, (2) Src kinase inhibition, (3) T-cell receptor-engineered T-cells (TCR-T), and (4) Arginine deprivation therapy. BUFFALO, N.Y.,

Engineering 52

Engineering Therapies Treatment International 52

The Pharma Data

DECEMBER 21, 2020

FDA Approves First Oral Hormone Therapy for Advanced Prostate Cancer. 21, 2020 — Orgovyx (relugolix) is now approved to treat advanced prostate cancer and is the first oral hormone therapy approved for this indication, the U.S. © 2020 HealthDay. Posted: December 2020. MONDAY, Dec. More Information.

FDA Approval 52

FDA Approval Therapies FDA Science 52

The Pharma Data

DECEMBER 14, 2020

15, 2020 08:40 UTC. LEIPZIG, Germany–( BUSINESS WIRE )– c-LEcta , a globally active biotechnology company with technology leadership in enzyme engineering and bioprocess development, successfully continued its growth in 2020 in what turned out to be a challenging year overall. Over 85 % of sales now come from products.

Production 52

Production Vaccine Engineering Therapies 52

The Pharma Data

DECEMBER 30, 2020

Using the contaminated mouthwash can result in “oral and, potentially, systemic infections requiring antibacterial therapy. © 2020 HealthDay. Posted: December 2020. Also, the recall of GUM Paroex Chlorhexidine Gluconate Oral Rinse is being expanded after manufacturer Sunstar Americas learned of 29 infections.

Vaccine 52

Vaccine Pharmacy Clinical Trials Packaging 52

The Pharma Data

NOVEMBER 20, 2020

20, 2020 — Hormone therapy can be a lifesaver for men with prostate cancer , but it also appears to put some at increased risk of heart problems, a new study reports. “We need to do everything we can to ensure the patients can receive lifesaving cancer therapy in a safe manner,” Ky said. FRIDAY, Nov.

Therapies 52

Therapies Doctors Disease Treatment 52

The Pharma Data

DECEMBER 30, 2020

The year 2020 will certainly go down in history as the year of COVID-19. Gilead Sciences Makes Multiple Bets : When Gilead Sciences wasn’t working on remdesivir in COVID-19, the company seemed to be constantly flexing its M&A muscle over the course of 2020. Nestlé Health Science has a history of advancing nutritional therapies.

Science 52

Science Disease Pharmaceuticals Treatment 52

The Pharma Data

SEPTEMBER 16, 2020

16, 2020 /PRNewswire/ — Amgen (NASDAQ:AMGN) will host two webcast calls for the investment community in conjunction with the European Society for Medical Oncology (ESMO) 2020 Virtual Congress. 20, 2020, at 11:00 a.m. THOUSAND OAKS, Calif. On Sunday, Sept. PDT, David M. Reese , M.D., Reese , M.D.,

Clinical Development 52

Clinical Development Therapies Disease Research 52

The Pharma Data

DECEMBER 9, 2020

9, 2020 — Side effects of radiation therapy in breast cancer patients are often missed by doctors, U.S. Of the more than 5,500 patients who reported at least one substantial side effect during radiation therapy, more than 53% had under-recognition of at least one of the four side effects. © 2020 HealthDay.

Therapies 52

Therapies Doctors Research Treatment 52

The Pharma Data

SEPTEMBER 24, 2020

NYSE:PFE) declared a 38-cent fourth-quarter 2020 dividend on the company’s common stock, payable December 1, 2020, to holders of the Common Stock of record at the close of business on November 6, 2020. The fourth-quarter 2020 cash dividend will be the 328 th consecutive quarterly dividend paid by Pfizer. Pfizer Inc.:

Government 40

Government Vaccine Science Therapies 40

The Pharma Data

DECEMBER 11, 2020

11, 2020 — Results from a long-term study of a gene therapy technique to prevent inherited mitochondrial disease show promise, researchers say. The therapy under investigation replaces disease-causing mutations in a mother’s egg with donor mitochondria. © 2020 HealthDay. Posted: December 2020.

Therapies 52

Therapies Clinical Trials Disease Trials 52

The Pharma Data

APRIL 22, 2023

The Atlas of MS reported in 2020 that someone is diagnosed with MS every five minutes around the world, adding to about 2.8 While no cure is available for MS, existing disease-modifying therapies in the form of small molecule and protein drugs either directly target the self-reactive immune cells or broadly dampen inflammation.

Therapies 40

Therapies Immune Response Small Molecule Engineering 40

The Pharma Data

NOVEMBER 18, 2020

19, 2020 /PRNewswire/ — Summary. Financial overview July 1 – September 30, 2020. Significant events during the period July 1 – September 30, 2020. 2020 Jul – Sep. 2020 Jan – Sep. STOCKHOLM , Nov. M (0.0).

FDA 40

FDA Pharmaceutical Companies Marketing Treatment 40

The Pharma Data

DECEMBER 5, 2020

5, 2020 — A pair of new gene therapies promise a potentially lasting cure for sickle cell disease by subtly altering the genetic information in patients’ bone marrow cells, researchers report. Both of the new gene therapy studies were published online Dec. SATURDAY, Dec. 5 in the New England Journal of Medicine.

Therapies 52

Therapies Disease Medical Schools Virus 52

The Pharma Data

OCTOBER 14, 2020

15, 2020 /PRNewswire/ — Thermo Fisher Scientific announced the launch of its Gibco CTS Rotea Counterflow Centrifugation System, a modular, closed cell therapy processing system that enables scalable, cost-effective cell therapy development and manufacturing. CARLSBAD, Calif. ,

Therapies 52

Therapies Clinical Trials Science Laboratories 52

The Pharma Data

SEPTEMBER 21, 2020

New data from two studies investigating the combination of Eisai’s multiple receptor tyrosine kinase inhibitor Lenvima (lenvatinib) and MSD’s blockbuster anti-PD-1 therapy Keytruda (pembrolizumab) were revealed at the European Society for Medical Oncology (ESMO) Virtual Congress 2020.

Therapies 52

Therapies Treatment Disease 52

The Pharma Data

SEPTEMBER 10, 2020

(NYSE:PFE) announced today that more than 50 abstracts representing data from nine approved and investigational Pfizer medicines, including several biomarker-driven and immuno-therapies, will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 being held from September 19-21, 2020. Mayer E. .

Therapies 52

Therapies Clinical Trials Production Trials 52

The Pharma Data

OCTOBER 27, 2020

28, 2020 02:29 UTC. NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, will report its third quarter 2020 operational and financial results on Tuesday, November 3, 2020 after the U.S. SOUTH SAN FRANCISCO, Calif.–(

Pharmaceutical Companies 40

Pharmaceutical Companies Therapies Production International 40

The Pharma Data

SEPTEMBER 1, 2020

Daiichi Sankyo has unveiled promising new benefit for Nilemdo (bempedoic acid) at the ESC Congress 2020 over the weekend for the management of low-density lipoprotein cholesterol (LDL-C) when added to other standards of care. compared to placebo on top of maximally tolerated statin therapy and other LLTs throughout the 78 weeks.

Clinical Trials 52

Clinical Trials Trials Treatment Therapies 52

The Pharma Data

DECEMBER 22, 2020

Tagrisso Approved as Adjuvant Therapy for NSCLC With EGFR Mutations. 22, 2020 — Tagrisso ( osimertinib ) received approval as an adjuvant treatment for patients with non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, the U.S. © 2020 HealthDay. Professional.

Therapies 52

Therapies Treatment FDA Disease 52

The Pharma Data

AUGUST 6, 2020

NEW YORK–( BUSINESS WIRE )– Bristol Myers Squibb (NYSE:BMY) today reports results for the second quarter of 2020, which reflect strong product sales, continued advancement of the pipeline and robust operating performance. billion, as of June 30, 2020. June 30, 2020 on. Second Quarter. . . Total Revenues.

Production 52

Production International Licensing Licensing 52

The Pharma Data

SEPTEMBER 10, 2020

European regulators have requested more data to review the marketing application for BioMarin’s haemophilia A gene therapy Valrox (valoctocogene roxaparvove). The EMA has asked for full data from an ongoing Phase III study of the treatment in patients with severe haemophilia A. Source link.

Therapies 52

Therapies Regulations Treatment Marketing 52

The Pharma Data

OCTOBER 26, 2020

ASTRO Issues Guideline on Radiation Therapy for Rectal Cancer. 26, 2020 — In a clinical practice guideline issued by the American Society for Radiation Oncology, published online Oct. © 2020 HealthDay. Posted: October 2020. Professional. MONDAY, Oct. Jennifer Y. . Abstract/Full Text. All rights reserved.

Therapies 52

Therapies Hospitals International Treatment 52

The Pharma Data

NOVEMBER 4, 2020

4, 2020 /PRNewswire/ — Gracell Biotechnologies Inc. (“Gracell”), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced two oral presentations at the 62 nd ASH Annual Meeting and Exposition in December.

Therapies 52

Therapies Treatment Production 52

Drug Channels

NOVEMBER 24, 2020

My recent tweets have highlighted: doctors against step therapy, distribution of COVID-19 therapies, biosimilar savings, copay accumulator data, prospects for smaller PBMs, the new transparency rule, specialty pharmacy profit metrics, the future of oncology practices, and an update on Diplomat founder Phil Hagerman. to 1:15 p.m.

Pharmacy 52

Pharmacy Specialty Pharmacies Biosimilars Drugs 52

The Pharma Data

NOVEMBER 19, 2020

20, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2020. Therapy Selection.

Hospitals 52

Hospitals Laboratories Marketing Research 52